DekaBank Deutsche Girozentrale Sells 6,645 Shares of Zoetis Inc. (ZTS)
DekaBank Deutsche Girozentrale lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 2.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 313,656 shares of the company’s stock after selling 6,645 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.06% of Zoetis worth $19,418,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Zoetis by 3.9% in the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after acquiring an additional 1,412,829 shares during the period. Vanguard Group Inc. boosted its position in shares of Zoetis by 2.8% in the second quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after acquiring an additional 910,265 shares during the period. Alliancebernstein L.P. boosted its position in shares of Zoetis by 55.4% in the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after acquiring an additional 3,695,449 shares during the period. American Century Companies Inc. boosted its position in shares of Zoetis by 7.2% in the second quarter. American Century Companies Inc. now owns 6,207,974 shares of the company’s stock valued at $387,253,000 after acquiring an additional 417,455 shares during the period. Finally, Janus Henderson Group PLC boosted its position in shares of Zoetis by 7,717.4% in the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock valued at $362,372,000 after acquiring an additional 5,734,776 shares during the period. 92.44% of the stock is owned by institutional investors.
WARNING: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/15/dekabank-deutsche-girozentrale-sells-6645-shares-of-zoetis-inc-zts.html.
A number of equities research analysts have recently issued reports on ZTS shares. BMO Capital Markets reissued a “hold” rating and issued a $65.00 target price on shares of Zoetis in a research report on Thursday, November 2nd. Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Monday, August 14th. Stifel Nicolaus reaffirmed a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research report on Friday, September 1st. BidaskClub cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. Finally, Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $67.06.
Shares of Zoetis Inc. (NYSE:ZTS) traded up $1.02 during midday trading on Wednesday, reaching $69.90. The company’s stock had a trading volume of 2,372,000 shares, compared to its average volume of 2,815,042. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The firm has a market capitalization of $33,564.42, a P/E ratio of 31.60, a price-to-earnings-growth ratio of 2.01 and a beta of 1.02. Zoetis Inc. has a 12-month low of $48.24 and a 12-month high of $70.48.
Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.52 earnings per share. equities research analysts forecast that Zoetis Inc. will post 2.36 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be paid a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Wednesday, November 8th. Zoetis’s payout ratio is 22.11%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.